JAMA Surgery on Mythryl: “Perioperative FLOT chemotherapy was linked to better survival and…”

Perioperative FLOT chemotherapy was linked to better survival and lower recurrence risk than CROSS chemoradiotherapy among esophageal adenocarcinoma patients achieving #pCR. ja.ma/4hcASDZ

ja.maFLOT vs CROSS in Esophageal AdenocarcinomaThis cohort study evaluates survival outcomes following FLOT chemotherapy vs CROSS chemoradiotherapy in patients with esophageal adenocarcinoma achieving pathological complete response.

17/9/26, 11:00 am1 repost1 like

Post